Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

Margherita Rimini; Masatoshi Kudo; Toshifumi Tada; S. Shigeo; Wonseok Kang; Goki Suda; André Jefremow; Valentina Burgio; Massimo Iavarone; Raffaella Tortora; Fabio Marra; Sara Lonardi; Emiliano Tamburini; Fabio Piscaglia; Gianluca Masi; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Takashi Kumada; Hideki Iwamoto; Tomoko Aoki; Myung Ji Goh; Naoya Sakamoto; Jürgen Siebler; Atsushi Hiraoka; Takashi Niizeki; Kazuomi Ueshima; Takuya Sho; Masanori Atsukawa; Masashi Hirooka; Kunihiro Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Naohiko Shimada; Hiroshi Shibata; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Shinya Fukunishi; Hideko Ohama; Kazuhito Kawata; Joji Tani; Shinichiro Nakamura; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Takaaki Tanaka; Norio Itokawa; Tomomi Okubo; T. Arai; Michitaka Imai; Kouji Joko; Yuma Koizumi; Yoichi Hiasa; Alessandro Cucchetti; Francesca Ratti; Luca Aldrighetti; Stefano Cascinu; Andrea Casadei‐Gardini

doi:10.1016/j.esmoop.2021.100330

Related publications

Article2022

Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib

Margherita Rimini, Wonseok Kang, Valentina Burgio, Mara Persano, Tamoko Aoki, Shigeo Shimose, Toshifumi Tada, Takashi Kumada, Takuya Sho, Eleonora Lai, Ciro Celsa, Claudia Campani, Matteo Tonnini, Emiliano Tamburini, Atsushi Hiraoka, Koichi Takaguchi, Naoshi Nishida, Hideki Iwamoto, Ei Itobayashi, Kunihiko Tsuji, Naoya Sakamoto, Toru Ishikawa, Hidenori Toyoda, Masatoshi Kudo, Takumi Kawaguchi, Takeshi Hatanaka, Kazuhiro Nouso, Goki Suda, Giuseppe Cabibbo, Fabio Marra, Angelo Della Corte, Francesca Ratti, Federica Pedica, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini

Article2017

Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC).

Masafumi Ikeda, Kenji Ikeda, Masatoshi Kudo, Yukio Osaki, Takuji Okusaka, Toshiyuki Tamai, Takuya Suzuki, Takashi Hisai, Hideaki Miyagishi, Kiwamu Okita, Hiromitsu Kumada

Article2022

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study.

Andrea Casadei‐Gardini, Margherita Rimini, Lorenza Rimassa, Valentina Burgio, Masatoshi Kudo, Toshifumi Tada, Shigeo Shimose, Goki Suda, Changhoon Yoo, Jaekyng Cheon, David J. Pinato, Mario Scartozzi, Stefano Cascinu

Dataset

Supplementary Material for: REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study

Andrea Casadei‐Gardini, M. Rimini, Masatoshi Kudo, S. Shimose, Toshifumi Tada, Goki Suda, Goh M.J., André Jefremow, Mario Scartozzi, Giuseppe Cabibbo, Claudia Campani, Emiliano Tamburini, Francesco Tovoli, Kazuomi Ueshima, Tomoko Aoki, Hiroki Iwamoto, Takuji Torimura, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Ei Itobayashi, Hideki Toyoda, Naoya Sakamoto, Sho T.,

Article2021

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Joji Tani, Kazuya Kariyama, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso,